Haematologica HAEMATOL/2017/185991 Version 3

A phase I/II dose-escalation study investigating all-oral ixazomib-melphalan-prednisone induction followed by single-agent ixazomib maintenance in transplant-ineligible newly diagnosed multiple myeloma

Jesús F. San-Miguel, Maria-Asunción Echeveste Gutierrez, Ivan picka, María-Victoria Mateos, Kevin Song, Michael D. Craig, Joan Bladé, Roman Hájek, Christine Chen, Alessandra Di Bacco, Jose Estevam, Neeraj Gupta, Catriona Byrne, Vickie Lu, Helgi van de Velde, and Sagar Lonial

Disclosures: JSM: reports advisory board from Takeda, Janssen, Novartis, Sanofi, Amgen, Celgene, MSD, BMS, and Roche, outside the submitted work. IS: has served as a consultant for, received research funding from, and holds membership on the board of directors or advisory committee of Celgene, Janssen-Cilag, Amgen, BMS, and Takeda. M-VM: has received honoraria derived from lectures and participation in advisory boards for Janssen, Celgene, Takeda, and Amgen, outside the submitted work. KS: has received honoraria from Takeda, and Celgene, outside the submitted work. JB: reports grants and personal fees from Celgene and Janssen, and personal fees from Amgen and Takeda, outside the submitted work. RH: reports grants, personal fees and non-financial support from Amgen, Takeda, Celgene, BMS, Janssen, and Novartis, outside the submitted work. AdB, JE, NG, CB, and VL. report employment by Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited. HvdV: reports employment by Sanofi and Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited. SL: reports consultancy scientific advice for Takeda, Celgene, Novartis, BMS, Amgen, BMS and Janssen. M-AEG, MC, CC: have nothing to disclose.

Contributions: Study design: JSM, AdB, NG, CB, VL, HvdV, SL Patient enrolment: JSM, MG, IS, M-VM, KS, MC, JB, RH, CC, SL Data collection: JSM, MG, IS, M-VM, KS, MC, JB, RH, CC, SL Data analysis: AdB, JE, NG, CB, VL, HvdV Data interpretation: AdB, JE, NG, CB, VL, HvdV Wrote or contributed to the writing of the manuscript: All authors Provided approval of the final manuscript version for submission: All authors